SNMMI 2023
SNMMI 2023
Jérémie Calais, MD, PhDSNMMI 2023 | March 11, 2024
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
View More
Emily MenendezSNMMI 2023 | June 29, 2023
Patients treated with enzalutamide prior to Lu-PSMA therapy had higher mean SUV values before treatment with 18 F-DCFPyL.
Emily MenendezSNMMI 2023 | July 5, 2023
68Ga-PSMA-11 and FDG-PET/CT scans were compared with scans from the VISION trial to assess patient eligibility for Pluvicto.
Emily MenendezSNMMI 2023 | June 29, 2023
The care management plans for several patients were changed after those patients underwent PSMA PET/CT.
Emily MenendezSNMMI 2023 | June 28, 2023
A research team developed a study to implement aPROMISE for the evaluation of PSMA and FDG-PET/CT scans acquired before RLT.
Emily MenendezSNMMI 2023 | July 11, 2023
A team of researchers compiled optimized methods for post-treatment radiation precautions for patients receiving Pluvicto.
Zachary BessetteSNMMI 2023 | August 16, 2023
New research identified genomic features and post-therapeutic SPECT/CT parameters as predictors of response to Pluvicto.
Zachary BessetteSNMMI 2023 | June 27, 2023
A study compared bone marrow dosimetry using three different methods for patients treated with 177Lu-PSMA-617.
Emily MenendezSNMMI 2023 | June 25, 2023
The proposed method of algorithm-based TTV produced comparable TTV and whole-body SUVmean levels.
Zachary BessetteSNMMI 2023 | June 25, 2023
Researchers compared the performance of Ga-68 PSMA PET/CT vs F-18-NaF PET/CT in detecting bone metastases in prostate cancer.
Emily MenendezSNMMI 2023 | June 27, 2023
An encoder-decoder network employing 3-dimensional convolutions was trained to segment regions that were suspected of cancer.